Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Renal toxicity association, renal-failure occurrence, and renal-function–dependent pharmacokinetics/dose adjustment are supported. However, many specific claims about monitoring (frequency, modalities, thresholds), clinical course labeling (AKI/CKD/ESRD), dialysis/transplant requirement, and mechanistic waste-product accumulation are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Acyclovir can be associated with renal toxicity.
WARNINGS: "Renal failure, in some cases resulting in death, has been observed with acyclovir therapy"; ADVERSE REACTIONS: "Renal failure... elevated blood urea nitrogen, elevated creatinine"
Renal toxicity with acyclovir is associated with patients with renal impairment (pre-existing kidney disease context).
PRECAUTIONS: "Dosage adjustment is recommended when administering acyclovir to patients with renal impairment"; ADVERSE REACTIONS (nervous symptoms): "These symptoms may be marked... in patients with renal impairment"
In impaired renal function, dose adjustment is recommended.
PRECAUTIONS: "Dosage adjustment is recommended... to patients with renal impairment"; DOSAGE AND ADMINISTRATION: "In patients with renal impairment... should be modified as shown in Table 3"
In impaired renal function, acyclovir pharmacokinetics are dependent on renal function (half-life and clearance).
CLINICAL PHARMACOLOGY: "The half-life and total body clearance of acyclovir are dependent on renal function"
Signs/symptoms of renal toxicity include elevated serum creatinine.
ADVERSE REACTIONS: "elevated creatinine"
Signs/symptoms of renal toxicity include elevated blood urea nitrogen (BUN).
ADVERSE REACTIONS: "elevated blood urea nitrogen"
Renal toxicity during acyclovir treatment can manifest as kidney failure.
WARNINGS: "Renal failure... has been observed"; ADVERSE REACTIONS: "Renal failure"
Acyclovir dosing schedule may be adjusted around hemodialysis.
DOSAGE AND ADMINISTRATION: "dosing schedule should be adjusted so that an additional dose is administered after each dialysis"
Unsupported Statements
The kidneys eliminate acyclovir and its metabolites from the body.
The provided label excerpts do not state elimination specifically by kidneys or describe renal elimination of metabolites.
In patients with impaired kidney function, the kidneys may clear acyclovir and its metabolites less effectively.
Label excerpt supports renal function affects half-life/clearance and dose adjustment, but does not explicitly state renal clearance of acyclovir and metabolites is less effective.
In patients with impaired kidney function, increased concentrations of acyclovir may lead to potential toxicity.
Label excerpts support renal-function–dependent PK and higher concentrations in older adults partly due to renal function, and renal failure observed, but do not explicitly connect “impaired kidney function -> increased concentrations -> potential toxicity.”
Patients with creatinine clearance (CrCl) less than 50 mL/min are at increased risk of acyclovir toxicity.
No CrCl <50 mL/min risk threshold is present in provided excerpts.
Monitoring kidney function during acyclovir treatment is essential to prevent renal toxicity.
The provided excerpts do not include monitoring instructions/recommendations.
If kidney function is impaired during acyclovir treatment, waste products including acyclovir can accumulate.
No label excerpt describes accumulation of “waste products” or acyclovir accumulation mechanism after impaired kidney function.
Accumulation of acyclovir due to impaired kidney function can lead to renal failure.
Label excerpts support renal failure observed and dose adjustment/renal-dependent PK, but do not explicitly state accumulation causes renal failure.
Regular monitoring of kidney function can identify patients at risk of renal impairment.
No monitoring recommendation is present in provided excerpts.
Regular monitoring of kidney function during acyclovir treatment can allow prompt intervention.
No monitoring/“prompt intervention” linkage is present in provided excerpts.
Kidney function can be monitored using serum creatinine.
Serum creatinine is cited as an adverse-reaction finding (“elevated creatinine”), but no monitoring method recommendation is provided.
Kidney function can be monitored using urine output.
Urine output monitoring is not mentioned.
Kidney function can be monitored using creatinine clearance.
Creatinine clearance appears in the dosing-modification table, but no label excerpt recommends monitoring kidney function via CrCl.
Renal toxicity during acyclovir treatment can manifest as acute kidney injury (AKI).
The excerpts use “renal failure” but do not describe AKI specifically.
Acute kidney injury (AKI) from acyclovir can be reversible or permanent.
The excerpts do not discuss reversibility/permanence.
Renal toxicity during acyclovir treatment can manifest as chronic kidney disease (CKD).
CKD is not mentioned.
Chronic kidney disease (CKD) from acyclovir can lead to end-stage renal disease (ESRD).
ESRD is not mentioned.
Kidney failure from acyclovir can require dialysis or kidney transplantation.
Dialysis scheduling guidance is present, but requirement for dialysis or transplantation due to renal failure is not stated.
Monitoring kidney function during acyclovir treatment is crucial, especially in patients receiving high doses.
No monitoring instruction is present; label excerpts do not state that high doses warrant kidney-function monitoring.
Regular monitoring every 2-3 days is recommended for patients with pre-existing kidney disease receiving high-dose acyclovir.
No monitoring frequency recommendation is present.
Signs and symptoms of acyclovir-induced renal toxicity include decreased urine output.
Decreased urine output is not mentioned.
In some cases, acyclovir-induced renal toxicity can be reversed with prompt intervention.
No reversibility statement is present.
Prompt intervention for acyclovir-induced renal toxicity can include discontinuation of the medication.
No label excerpt provides management steps like discontinuation.
Prompt intervention for acyclovir-induced renal toxicity can include supportive care.
No label excerpt provides management steps such as supportive care.
A patient prescribed acyclovir for HSV developed acute kidney injury after 2 weeks of treatment when kidney function was not monitored.
No case description or timeline is present in provided excerpts.
In the described case, the patient required hospitalization and dialysis after acyclovir-associated acute kidney injury.
No case description is present in provided excerpts.
Patients receiving high doses of acyclovir should be closely monitored.
No monitoring recommendation is present in provided excerpts.
The recommended frequency of kidney function monitoring during acyclovir treatment may vary depending on the patient's kidney function and the dose.
No monitoring frequency recommendation is present.
Patients with normal kidney function can still develop acyclovir-induced renal toxicity, particularly if they receive high doses.
The excerpts confirm renal failure observed, but do not specify occurrence in those with normal kidney function or link to high doses.
Contradictions
Low
AI Statement
In patients with impaired kidney function, the kidneys may clear acyclovir and its metabolites less effectively.
Label Reference
CLINICAL PHARMACOLOGY: half-life/clearance dependent on renal function; PRECAUTIONS/DOSAGE: dosage adjustment for renal impairment
Important Omissions
Specific label-supported dosing modifications for renal impairment (Table 3) were not discussed where the claims focused on monitoring; this affects safe implementation of label direction for renal impairment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most general renal-toxicity association is label-supported, but several precise monitoring and outcome/course assertions (frequency, modalities, AKI/CKD/ESRD, reversibility, dialysis/transplant requirement) are not supported by the provided excerpts, which could mislead protocol decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Over-specific renal monitoring and clinical-course claims are not supported by the provided label excerpts.
Suggested Improvement
Restrict statements to label-supported content (renal failure observed; adverse reaction lab abnormalities; renal-function–dependent PK; and that dosage adjustment is recommended in renal impairment with Table 3 dosing modifications). Remove unsupported monitoring frequency/modalities and AKI/CKD/ESRD/dialysis/transplant/course/reversibility assertions unless supported by additional label sections.